A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

Published 2015 View Full Article

Authors

Keywords

Endometrial cancer, Angiogenesis, Trebananib, NCT01210222

Journal

GYNECOLOGIC ONCOLOGY

Volume 138, Issue 3, Pages 513-518

Publisher

Elsevier BV

Online

2015-07-12

DOI

10.1016/j.ygyno.2015.07.006

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started